As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Most recently, Amgen shares advanced in 2Q following its announcement that its novel injectable GLP-1 agonist / GIPR antagonist, MariTide, for obesity, showed promising interim Phase 2 data and ...

Amgen has initiated two “critical” late-stage trials for its experimental weight loss injection, MariTide. MariTide is a monthly injection designed to compete with existing weekly GLP-1 weight ...

Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...

Most recently, Amgen shares advanced in 2Q following its announcement that its novel injectable GLP-1 agonist / GIPR antagonist, MariTide, for obesity showed promising interim Phase 2 data and has ...

This positive outcome has led Bernstein analysts to adjust their price target for Amgen shares to $350, despite ongoing uncertainties surrounding the MariTide product. In contrast, Piper Sandler ...

Top-line phase 2 results with Amgen's MariTide drug for obesity are finally in – but the highly anticipated doesn't seem to have lived up to investor expectations. MariTide (maridebart ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...